Recent Updates
Recently added Catalysts
QURE Negative Sentiment Score: 25/100

uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE

Key Takeaway: ClaimsFiler has issued a reminder for uniQure N.V. investors to file lead plaintiff applications in a class action lawsuit. The lawsuit concerns alleged violations of federal securities laws, related to the company's failure to disclose material information regarding its drug AMT-130 during its Class Period. Following a significant correction in share price after a disclosure from the FDA, a drop of over 49% was noted. The deadline for potential plaintiffs is April 13, 2026.

Market Sentiment Analysis

CONCERNS & RISKS

  • uniQure's stock price fell over 49% following a significant disclosure about its drug AMT-130.
  • The company failed to meet the FDA's expectations for data adequacy, impacting its BLA submission timeline.
  • Investors who purchased shares during the class period are now confronted with legal action and potential losses.

Full Press Release Details

NEW ORLEANS, April 02, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (“uniQure” or the “Company”), if they purchased or otherwise acquired the Company’s shares between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
uniQure investors should visit us at https://claimsfiler.com/cases/nasdaq-qure/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
uniQure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
During the Class Period, the Company represented to investors that there was a high likelihood that its leading drug candidate, AMT-130, would receive accelerated approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s planned Biologics License Application (“BLA”) submission in the first quarter of 2026. However, on November 3, 2025, the Company disclosed that “the FDA currently no longer agrees that the data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission” and as a result, “the timing of the BLA submission for AMT-130 is now unclear.”
On this news, the price of uniQure’s shares plummeted $33.40 per share, or more than 49%, from a close of $67.69 per share on October 31, 2025, to close at $34.29 per share on November 3, 2025.
The case is Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file lead plaintiff applications?

Investors have until April 13, 2026, to file lead plaintiff applications.

What was uniQure accused of during the Class Period?

uniQure is charged with failing to disclose important information and violating laws.

What triggered the drop in uniQure's share price?

The share price fell over 49% after the FDA's concerns about AMT-130's approval.

Who can help with legal options for uniQure investors?

Lawyers at Kahn Swick & Foti, LLC are available to discuss legal options.

How can investors keep updated on securities cases?

Investors can register at ClaimsFiler to receive timely updates on cases.

Last updated: Apr 2, 2026